Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01417234 · ClinicalTrials.gov registry record
Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System for Treatment of Acute Trauma and Acute Surgical Excision Wounds
A clinical trial of Trauma-related Wound and Surgical Wound, Recent, sponsored by 3M.
- Completed
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT01417234: Completed study of Trauma-related Wound and Surgical Wound, Recent, sponsored by 3M.
NCT01417234 is a study of Trauma-related Wound and Surgical Wound, Recent that has completed, run by 3M. The registered enrollment target is 30 participants, above the 23-participant average among 3 other Trauma-related Wound trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01417234, a study of Trauma-related Wound and Surgical Wound, Recent, has completed, sponsored by 3M.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of the Spiracur SNaP® Wound Care System for the treatment of acute trauma and acute surgical excision wounds. The secondary purpose will be to compare the prospective patients to retrospectively treated acute trauma wounds to further evaluate efficacy and safety.
Primary Outcome
Percent of subjects with study wound deemed closed at 12 weeks 1 wound is studied per participant
Conditions Studied
Interventions
- DEVICE SNaP® Wound Care System
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-10 |
What the finished NCT01417234 record still lists
NCT01417234 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, above the 23-participant average among 3 other Trauma-related Wound trials with a reported enrollment target (30% higher).
The record links to 2 conditions, with Trauma-related Wound appearing as the primary indexed condition, and to 1 intervention - of which SNaP® Wound Care System is the first listed.
NCT01417234 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01417234 about?
NCT01417234 is a clinical study titled "Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System for Treatment of Acute Trauma and Acute Surgical Excision Wounds". The purpose of this study is to evaluate the efficacy of the Spiracur SNaP® Wound Care System for the treatment of acute trauma and acute surgical excision wounds. The secondary purpose will be to compare the prospective patients to retrospectively treated acute trauma wounds to further evaluate eff...
What is the current status of trial NCT01417234?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2011-06. Estimated completion is 2012-10.
What conditions does trial NCT01417234 study?
This clinical trial studies the following conditions: Trauma-related Wound, Surgical Wound, Recent.
What interventions are being tested in trial NCT01417234?
The interventions under investigation include: SNaP® Wound Care System (DEVICE).
Who is sponsoring clinical trial NCT01417234?
This trial is sponsored by 3M, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01417234 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trauma-related Wound
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
COMPLETED · Phase 1
-
Procellera® Compared to Standard of Care Treatment in Mitigating Biofilm Formation in Acute Trauma and Burn Wounds
COMPLETED · NA
-
StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia